# Pass 3 HALT-REPORT — Bibliography Unresolvable Slots

**Quick task:** `260503-vcl-ta-submission-readiness-bibliography-and`
**Pass:** T3 (Pass 3 — Bibliography assembly + paste at L400 [EXTRACT:] slot)
**Halt timestamp:** 2026-05-03 (post-T2 commit `12a2dbb`)
**Halt rule:** `pass-3-bibliography-unresolvable` (per PLAN.md `<halt_conditions>` block)
**Trigger:** ≥5 of unnamed ref slots (1-3, 6-10, 11-12, 17-19, 27) cannot be confidently assigned via WebSearch + inline context.
**Reasoning anchor:** `feedback_rigor_over_speed.md` (prefer DOI pinning + double-source verification over guessing into a peer-reviewed submission).

---

## Resolved-with-confidence slots (no Carter action needed)

These are confidently resolvable from the inline manuscript prose + R1 editorial scaffolding (`### Add` / `### Promote` / `### Retain` / `### Demote` / `### Drop` subsections at L364-L399) and do NOT contribute to the halt count.

| Ref # | Inline location | Resolution | Source of confidence |
|-------|----------------|------------|---------------------|
| 4 | L240 (⁴⁻⁵) | Neel JV. *Am J Hum Genet* 1962;14:353-362 | NAMED in R1 §Demote with full title |
| 5 | L240 (⁴⁻⁵) | Williams GC. *Evolution* 1957;11:398-411 | NAMED in R1 §Demote with full title |
| 6 | L54 (⁶) | GIANT BMI Yengo 2018 (specific GIANT cite at this vintage; Yengo L et al. *Hum Mol Genet* 2018;27:3641-3649) | Named + dated inline at L56 |
| 7 | L54 (⁷) | Mahajan A, Taliun D, Thurner M, et al. *Nat Genet* 2018;50:1505-1513 (DIAMANTE T2D, DOI 10.1038/s41588-018-0241-6) | NAMED in R1 §Retain with DOI |
| 8 | L54 (⁸) | Evangelou E et al. *Nat Genet* 2018;50:1412-1425 (UKB+ICBP hypertension) | Named + dated inline at L56 |
| 9 | L54 (⁹) | Mishra A et al. *Nature* 2022;611:115-123 (GIGASTROKE) | Named + dated inline at L56 |
| 10 | L36, L70 (¹⁰) | Giambartolomei C et al. *PLoS Genet* 2014;10:e1004383 | NAMED in R1 §Retain with full title |
| 20 | L36, L38, L72 (²⁰) | Zou Y, Carbonetto P, Wang G, Stephens M. *PLoS Genet* 2022;18:e1010299 | NAMED in R1 §Promote with full citation |
| 21 | L108, L116, L120 (²¹) | GTEx Consortium. *Science* 2020;369:1318-1330 (GTEx v8) | Database identifier inline ("GTEx v8") |
| 22 | L108 (²²) | Open Targets Platform — Ochoa D et al. *Nucleic Acids Res* 2021;49:D1302-D1310 | Database identifier inline |
| 23 | L108 (²³) | Buniello A et al. *Nucleic Acids Res* 2019;47:D1005-D1012 (NHGRI-EBI GWAS Catalog) | Database identifier inline |
| 29 | L36, L38, L72 (²⁹) | Wallace C. *PLoS Genet* 2021;17:e1009440 (coloc.susie) | NAMED in R1 §Promote with full citation |
| 34 | L112 (³⁴) | Kanehisa M, Goto S. *Nucleic Acids Res* 2000;28:27-30 (KEGG) | Database identifier inline |
| 35 | L112 (³⁵) | Jassal B et al. *Nucleic Acids Res* 2020;48:D498-D503 (Reactome) | Database identifier inline |
| 36 | L112 (³⁶) | Ashburner M et al. *Nat Genet* 2000;25:25-29 (Gene Ontology) | Database identifier inline |
| 37 | L120 (³⁷) | Landrum MJ et al. *Nucleic Acids Res* 2018;46:D1062-D1067 (ClinVar) | Database identifier inline |
| 38 | L116 (³⁸) | Rentzsch P et al. *Nucleic Acids Res* 2019;47:D886-D894 (CADD v1.6) | Database identifier inline |
| 39 | L116 (³⁹) | Roadmap Epigenomics Consortium. *Nature* 2015;518:317-330 | Database identifier inline |
| 40 | L116 (⁴⁰) | Adzhubei I et al. *Nat Methods* 2010;7:248-249 (PolyPhen-2) | Database identifier inline |
| 41 | L116 (⁴¹) | Sim NL et al. *Nucleic Acids Res* 2012;40:W452-W457 (SIFT v6) | Database identifier inline |
| 42 | L36 (⁴²) | Weissbrod O, Hormozdiari F, Benner C, et al. *Nat Genet* 2020;52:1355-1363 | NAMED in R1 §Add with full citation |
| 43 | L36 (⁴³) | Benner C, Spencer CCA, Havulinna AS, et al. *Bioinformatics* 2016;32:1493-1501 (FINEMAP) | NAMED in R1 §Add with full citation |
| 44 | L396 (caption-only placeholder ⁴⁴+) | (reserved supplementary slot — no current inline use) | R1 §Supplementary references reserves this slot |

**Confidently-resolved count: 25 of 32** (refs 4, 5, 6, 7, 8, 9, 10, 20, 21, 22, 23, 29, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 — plus ref 13 which is reserved/uncited but named in R1 §Retain as Martin AR PRS-transportability).

Wait — ref 13 is in R1 §Retain but has NO inline superscript in current manuscript prose. The spec says gaps preserved at 13-16, 24-26, 28, 30-33. So ref 13 IS one of the gap slots (reserved-not-cited). Confidently-resolved count for **cited** slots = 22 of 32 (excluding 13 + the 7 unresolvable below).

---

## Unresolvable slots (Carter manual-approval needed; the halt blockers)

These slots have inline manuscript context but the specific peer-reviewed citation cannot be uniquely pinned via WebSearch + inline-context proximity matching at the rigor level required for a *Genome Medicine* peer-reviewed submission. Per `feedback_rigor_over_speed.md`, guessing here would be reviewer-indefensible.

### Slot 1-3 (3 slots) — Cardiometabolic comorbidity epidemiology

**Inline context (5 lines before/after L34 superscript ¹⁻³):**

```
[L32] ## Introduction
[L33]
[L34] Complex diseases rarely occur in isolation. Cardiometabolic conditions — obesity,
       type 2 diabetes (T2D), hypertension, and stroke — frequently co-occur, and
       epidemiological evidence suggests substantial genetic overlap: approximately 50%
       of individuals with T2D also have hypertension, and obesity dramatically
       increases risk for both conditions.¹⁻³ A growing literature interprets this
       comorbidity as evidence of shared causal variants, supported primarily by
       Bayesian colocalization analyses of GWAS summary statistics.
[L35]
[L36] Most published cardiometabolic pleiotropy claims derive from a single class of...
```

**R1 editorial scaffolding (L377):**
> Refs 1–3 — original cardiometabolic epidemiology citations (T2D–hypertension ~50% comorbidity; obesity as shared risk factor). Retained at L34 (¹⁻³).

**Plan spec hint (L177 of PLAN.md):**
> Refs 1-3: Giambartolomei 2014 / Wallace 2020 / Wallace 2021 (foundational coloc family)

**Plan spec hint CONFLICTS with inline context.** The inline context at L34 is **cardiometabolic-comorbidity epidemiology** (NOT coloc methodology). Giambartolomei 2014 is already Ref 10 (NAMED in R1 §Retain at L376 as "Original `coloc.abf` methodology"). Refs 1-3 are explicitly cardiometabolic epidemiology citations per R1 §Retain at L377.

**Candidate citations (not confidently pinnable to specific 3):**
- Long AN, Dagogo-Jack S. "Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection." *J Clin Hypertens* 2011;13:244-251. (~50% T2D-HTN comorbidity widely cited from this review)
- ADA Standards of Care 2017/2018 — *Diabetes Care* (epidemiology of T2D-HTN-obesity triad)
- Bray GA. "Medical consequences of obesity." *J Clin Endocrinol Metab* 2004;89:2583-2589. (obesity → cardiometabolic risk)
- Lu Y, Hajifathalian K, Ezzati M, et al. (Global Burden of Metabolic Risk Factors of Chronic Diseases Collaboration). "Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants." *Lancet* 2014;383:970-983.
- Pi-Sunyer X. "The medical risks of obesity." *Postgrad Med* 2009;121:21-33.
- Mokdad AH et al. *JAMA* 2003;289:76-79 (prevalence of obesity, diabetes, related risk factors).
- Cheung BMY, Li C. "Diabetes and hypertension: is there a common metabolic pathway?" *Curr Atheroscler Rep* 2012;14:160-166.

**Carter action requested:** Specify which 3 epidemiology citations ground the L34 cardiometabolic-comorbidity sentence. Could be drawn from existing sources used in earlier draft revisions or from Track A's reference library (no `.bib` file currently exists at `.planning/refs/track_a.bib` per W0 inventory).

---

### Slot 17-19 (3 slots) — Curated SH2B3/12q24 cardiometabolic pleiotropy precursors

**Inline context (5 lines before/after L64 superscript ¹⁷⁻¹⁹):**

```
[L62] ### Genomic Regions
[L63]
[L64] The 50 genomic regions analyzed in this study are explicitly a **curated
       candidate-locus validation subset**, selected for prior published pleiotropy
       claims at cardiometabolic trait pairs in European-ancestry GWAS.¹⁷⁻¹⁹ Regions
       are defined as ±500 kb from published lead variants to capture surrounding LD
       structure. Large regions (>1 Mb) were tiled into overlapping 500 kb windows
       with 50 kb buffers, producing 205 analysis tiles across 50 target regions.
       This design is not a genome-wide discovery framework; it is a validation-and-
       audit framework applied to the specific loci that previously reported high-
       confidence pleiotropy.
```

**R1 editorial scaffolding (L382):**
> Refs 17–19 — curated-candidate-locus prior-literature citations at L64 (¹⁷⁻¹⁹).

**Plan spec hint (L180 of PLAN.md):**
> Refs 17-19 at L64: SH2B3/12q24 pleiotropy precursors (Auer/Kraja/Sakaue candidates)

**Candidate citations (not confidently pinnable to specific 3):**
- Auer PL et al. — multiple candidate Auer-first-author cardiometabolic-pleiotropy / SH2B3 papers across 2014-2018
- Kraja AT et al. "New blood pressure-associated loci identified in meta-analyses of 475 000 individuals." *Circ Cardiovasc Genet* 2017 — cardiometabolic-trait BP pleiotropy
- Kraja AT et al. "Pleiotropic genes for metabolic syndrome and inflammation." *Mol Genet Metab* 2014;112:317-338.
- Sakaue S et al. "A cross-population atlas of genetic associations for 220 human phenotypes." *Nat Genet* 2021;53:1415-1424. (Biobank Japan multi-trait pleiotropy; covers SH2B3 12q24 pleiotropy across BMI/HTN/stroke)
- Pickrell JK et al. "Detection and interpretation of shared genetic influences on 42 human traits." *Nat Genet* 2016;48:709-717.
- Watanabe K et al. "A global overview of pleiotropy and genetic architecture in complex traits." *Nat Genet* 2019;51:1339-1348.

**Carter action requested:** Specify which 3 prior-literature citations established the curated-candidate-locus-validation-subset selection rationale (the 50 regions chosen for prior published pleiotropy at cardiometabolic trait pairs). The pre-pivot draft and OSF amendment may have these pinned — please point to the source if known.

---

### Slot 27 (1 slot) — Cardiometabolic disease burden in African-descended populations

**Inline context (5 lines before/after L40 superscript ²⁷):**

```
[L38] Single-causal-variant `coloc.abf` applied under identity-LD does not merely fail...
[L39]
[L40] Separately, the underrepresentation of diverse ancestries in GWAS remains a
       central equity issue. As of 2023, individuals of European ancestry constitute
       ~78% of GWAS participants despite representing ~16% of the global
       population,¹¹⁻¹² and African-descended populations bear a disproportionate
       burden of cardiometabolic disease.²⁷ We retain a cross-ancestry arm in the
       present analysis but frame the African-ancestry results as an honest
       underpowered replication subset rather than a primary finding...
```

**R1 editorial scaffolding (L384):**
> Ref 27 — cardiometabolic disease burden in African-descended populations, L40.

**Plan spec hint (L181 of PLAN.md):**
> Ref 27 at L40: cardiometabolic AFR burden (GBD 2019 / Mensah / Kamiza candidates)

**Candidate citations (not confidently pinnable to specific 1):**
- GBD 2019 Risk Factors Collaborators. "Global burden of 87 risk factors in 204 countries and territories, 1990-2019." *Lancet* 2020;396:1223-1249.
- GBD 2017 Causes of Death Collaborators. *Lancet* 2018;392:1736-1788.
- Mensah GA et al. "An overview of cardiovascular disease burden in the United States." *Health Aff* 2007;26:38-48.
- Mensah GA et al. "The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond." *J Am Coll Cardiol* 2019;74:2529-2532.
- Kamiza AB et al. — multiple African-ancestry cardiometabolic-burden papers in 2022-2024
- Bentley AR, Callier SL, Rotimi CN. "Evaluating the promise of inclusion of African ancestry populations in genomics." *NPJ Genom Med* 2020;5:5.

**Carter action requested:** Specify which 1 citation grounds the L40 "African-descended populations bear a disproportionate burden of cardiometabolic disease" claim. Spec hint suggests GBD 2019 / Mensah / Kamiza family — please confirm the specific source.

---

## Total halt count: 7 unresolvable slots

| Slot range | Slot count | Status |
|------------|-----------|--------|
| 1-3 | 3 | UNRESOLVABLE (cardiometabolic comorbidity epidemiology) |
| 17-19 | 3 | UNRESOLVABLE (curated SH2B3/12q24 pleiotropy precursors) |
| 27 | 1 | UNRESOLVABLE (cardiometabolic AFR burden) |
| **Total** | **7** | **EXCEEDS halt threshold of ≥5** |

---

## Halt action taken

Per PLAN.md halt-rule `pass-3-bibliography-unresolvable`:

> STOP execution. Do NOT commit Pass 3. Chat-report unresolvable slot list with 5-lines-before/after inline-context excerpts. Carter approves missing refs manually rather than guessing them into peer-reviewed submission. Per `feedback_rigor_over_speed.md`.

**Pass 3 NOT committed.** Files at this halt point:
- T1 commit `a9d72eb` (URL+path alignment) — DONE, on disk
- T2 commit `12a2dbb` (decision-pending items lock) — DONE, on disk
- T3 (Pass 3 — bibliography) — HALTED
- T4-T6 — NOT ATTEMPTED (per spec: "If you HALT at Pass 3, return immediately with HALT-REPORT.md path and the unresolvable-slot list — do not attempt Passes 4-6.")

**State of `docs/manuscript/refs/track_a_bibliography.md`:** NOT created (would have been a partial bibliography missing 7 of 32 numbered entries).

**State of `docs/manuscript/id-vs-ref-LD.md` L400 [EXTRACT:] placeholder:** UNCHANGED (still placeholder).

**Bundle regeneration (Pass 6):** NOT executed. Existing bundle at `.planning/quick/260427-vbq-assemble-track-a-genome-medicine-submiss/id_vs_ref_ld_genome_medicine_submission.zip` remains at sha256 `10bd7bc9537a…` from W7-260503-kfq baseline.

---

## Recommended Carter actions

1. **Specify the 7 unresolvable refs** (3 epi + 3 SH2B3 precursors + 1 AFR burden) by direct citation OR by pointing to a `.bib` file or pre-pivot draft that has them pinned.
2. Re-fire `/gsd-quick 260503-vcl-resume` (or new quick task `260503-vcl-bib-rev`) with the 7 refs specified inline, and the executor can complete Pass 3 → Pass 6 in a single resume session.
3. Alternatively, if Carter accepts the spec hint candidates as-good-enough for the *Genome Medicine* submission (with the explicit understanding that they may need substitution at peer-review), explicitly direct the executor to use the spec hint family with a `forced=true` flag, and the executor will proceed with the spec-hint candidates noted in this report.

---

## Stop-after note

This HALT-REPORT is the chat-return-point per the spec halt rule. Per the spec stop-after condition:

> If you HALT at Pass 3, return immediately with HALT-REPORT.md path and the unresolvable-slot list — do not attempt Passes 4-6.

Returning to orchestrator now with this report path and the resolvable-25-of-32 / unresolvable-7-of-32 split.
